

CURRICULUM VITAE

Maria Teresa Scupoli

Personal data

Citizenship: Italian

Place and date of birth: Taranto (Italy), January 18, 1963

Education

- 1997-2002: PhD in Biotechnology Applied to Biomedical Science, University of Verona.
Research: Immunobiology, Experimental Hematology. Functional interplaying between normal immature T lymphocytes and bystander cells in thymic microenvironment.
Scientific advisors: Prof. Giovanni Pizzolo
- 1994-1997: Board certified in Genetics with full marks and honors, University of Bologna.
Research: Immunobiology. Effects of thymic microenvironment on immature T-cell biology: the regulatory role of NF- κ B.
Scientific advisor: Prof. Domenico Palenzona
- 1982-1987: Master's Degree in Biology with full marks and honors, University of Bologna.
Thesis dissertation: Kinetic measurements of electron transfer in coupled chromatophores from photosynthetic bacteria. A method of correction for the electrochromic effects.
Scientific advisor: Prof. Bruno Andrea Melandri

Experience and employment

- 2019-today: Member of the Board of ISCCA (Italian Society for Cytometric Cell Analysis)
- 2018-today: Associate Professor of Applied Biology, School of Medicine, Dept. of Neurosciences, Biomedicine, and Movement
- 2004-today: Chief of the Research Center LURM (Laboratorio Universitario di Ricerca Medica), University of Verona
- 2009-today: Chief of the Flow Cytometry and Cell Sorting Platform, Center of Applied Research on Cancer–Network (ARC-Net), University of Verona
- 2012-2015: Member of the Board of Directors – University of Verona
- 2002-2003: Research Assistant, Department of Medicine, Hematology Section, University of Verona
Research: Experimental Hematology. Influence of neoplastic microenvironments on the biology of leukemic states.
- 2000: Academic Visitor, Prof. Mary Ritter's laboratory, Department of Immunology– Faculty of Medicine- Imperial College School of Medicine- London.
Research: Immunobiology, Experimental Hematology. Influence of thymic microenvironment on the biology of leukemic states.
- 1995-1996: Italian Institute of Health (ISS) Research Fellow, Department of Pathology, Immunology Section, University of Verona

Research: Immunobiology. Functional interplaying between thymic epithelial cells and immature T lymphocytes in the thymic microenvironment: role of adhesion molecules and NF- κ B proteins in gene transcription and cell survival.

Scientific advisor: Dr. Dunia Ramarli

1991-1993: Italian Association for Cancer Research (AIRC) Fellow, Department of Pathology, Immunology Section, University of Verona

Research: Immunogenetics, Gene expression. Regulation of MHC class-II antigen expression in normal and neoplastic states.

Scientific advisor: Prof. Roberto S. Accolla

Awards and eligibility

Award GILEAD Sciences. "Fellowship Program". An antioxidant signature as a newer prognostic model in chronic lymphocytic leukemia. 2019-2020.

Award "Alessandro Moretta" for the best oral abstract presentation at the ISCCA (Italian Society for Cytometric Cell Analysis) Conference, November 8-10, 2018. Rome

Eligible to be appointed as full professor for Applied Biology (Abilitazione Scientifica Nazionale 2016 per Biologia Applicata, BIO/13)

Award for the best oral abstract presentation at the ESCCA (European Society for Clinical Cell Analysis) Conference, September 11-14, 2016. Edinburgh

Award for a scientific contribute to the XVIII congresso Nazionale dell'Associazione italiana per lo studio del pancreas, June 17-18, 1994. Milan

Scientific interest

I have a consolidate experience as scientist in the field of cellular and molecular cancer biology, as shown by several first-, last-, or corresponding-author research papers in international peer-reviewed scientific journals. Since 2004, I have been principal investigator of a research group focused on studying molecular mechanisms and signaling transduction pathways activated by microenvironmental stimuli that regulate leukemia progression. Besides standard molecular and cell biology techniques, I have consolidated expertise in characterizing signaling transduction properties at a single cell level using phospho-specific flow cytometry, which allows to simultaneously determine protein expression and protein post-translational modifications (i.e. phosphorylation) at a single cell level, thus providing a network-level view of cell signaling.

My studies are focused on chronic lymphocytic leukemia (CLL). Particularly, my current interest is aimed at characterizing signal transduction pathway downstream the B cell receptor, which is considered a key determinant of CLL clinical behavior. These studies allowed to identify BCR signaling nodes that are relevant in leukemia progression (*Cesano et al, Haematologica 2013*) and to integrate signaling properties with the presence of driver-gene mutations for a more precise definition of the cellular pathological state and its impact on disease evolution (*Cavallini et al, Haematologica 2017*). More recently, my group has identified redox properties that are associated with a dismal prognosis of the disease (*Cavallini et al, Blood 2018*).

Research support

Award GILEAD Sciences. "Fellowship Program". An antioxidant signature as a newer prognostic model in chronic lymphocytic leukemia. 2019-2020. Role: PI

Fondazione Cariverona. Biomarkers in Oncology. 2016-2017. Role: participant.

AIRC (Associazione Italiana Ricerca sul Cancro). Regional research program 2008. An integrated approach to chronic lymphoproliferative disorders: B-CLL and virus-related neoplasia. 2009-2016. Role: participant as senior investigator to 09/30/2014; scientific coordinator (PI) from 10/01/2014 to 31/07/2016.

Fondazione Cariverona 2008 - Autoimmunità nella leucemia linfatica cronica. Studio dei meccanismi dipendenti dalla leucemia che regolano il differenziamento e l'attivazione dei linfociti T e delle cellule dendritiche. 2009-2010. Role: scientific coordinator (PI).

COFIN/MIUR 40% - Analisi dei meccanismi coinvolti nell'effetto immunoregolatorio delle cellule staminali mesenchimali midollari umane. 2005-2007. Role: participant.

Ricerca Sanitaria Finalizzata Regionale 2006 - Progetto Istituto Oncologico Veneto (IOV). Razionalizzazione e standardizzazione di diagnosi e terapia della leucemia linfatica cronica: attivazione di una rete tra strutture ematologiche nella Regione Veneto. 2007-2008. Role: participant.

Fondazione Cariverona 2003 - Microambiente e progressione neoplastica: il network di regolazione indotto da cellule stromali. Biologia e applicazioni terapeutiche. 2004-2005. Role: unit scientific coordinator (PI).

Manuscript and grant peer reviews

Scientific journals: Blood; Haematologica; Journal of Proteomics; Scientific Reports; Journal of Translational Medicine; Leukemia Research; Cancers; Cancer Cell International; BMJ Open.

Grant applications: Leukaemia & Lymphoma Research (LLR), UK; HRZZ – Croatian Science Foundation, HR; Bloodwise, UK.

Teaching experience

AY 2018-19	Teacher: Applied Biology (BIO/13). Course for Master's Degree in Dentistry, University of Verona
AY 1996-97	Lecturer and Faculty member: Immunology, Course for Bachelor's Degree in Nursing School of Medicine, University of Verona
AY 1996-97	Lecturer and Faculty member: Immunology and Immunohematology, Course for Bachelor's Degree in Nursing, School of Medicine, University of Verona
AYs 1995-96 and 1996-97	Lecturer and Faculty member: Cell Culture Techniques, Course for Bachelor's Degree in Laboratory Technician, School of Medicine, University of Verona

Meeting organization, speaker and chairman

Invited Speaker: "Phosphoprotein Analysis", Course "Intracytoplasmic labeling" – Congress of the "Italian Society for Cytometric Cell Analysis" (ISCCA). November 8-10, 2018. Rome, Italy

Chairman: Congress of the "Italian Society for Cytometric Cell Analysis" (ISCCA). Session: Functional flow cytometry. November 8-10, 2018. Rome, Italy

Speaker: "Characterization of redox signaling sensitivity associated with leukemia disease progression by phospho-specific flow cytometry" - Congress of the "European Society for Clinical Cell Analysis" (ESCCA). September 24-27, 2017. Thessaloniki, GR

Speaker: "Phospho-specific flow cytometry for characterizing redox signaling sensitivity associated with leukemia disease progress" - Congress of the "Italian Society for Cytometric Cell Analysis" (ISCCA). May 8-10, 2017. Bologna, Italy

Speaker: "Integrate single cell network profiling data of ERK signaling and mutations of SF3B1 gene refine prognosis in chronic lymphocytic leukemia" - Congress of the "European Society for Clinical Cell Analysis" (ESCCA). Session: "Best Oral Abstract Presentations". September 11-14, 2016. Edinburgh, UK

Chairman: 58th Annual Meeting of the Italian Cancer Society. Session: Drug resistance, signal transduction, targeted therapy. September 5-8, 2016. Verona, Italy

Invited speaker: "Analysis of signaling profiles in chronic lymphocytic leukemia" – Congress of the "European Society for Clinical Cell Analysis" (ESCCA). October 30, 2015. Giardini Naxos (CT), Italy

Invited speaker: "The tumor microenvironment: molecular cross-talk and new opportunity" – New Perspectives in Hematology. September 26, 2014. Verona, Italy

Scientific organizer: Advanced course in flow cytometry: applications in Oncology and Immunology. Session: Cellular Functions. May 22-23, 2012. Verona, Italy

Chairman: Advanced course in flow cytometry: applications in Oncology and Immunology. Session: Cellular Functions. May 22-23, 2012. Verona, Italy

Invited speaker: "The single cell network profiling in the prognostic characterization of chronic lymphocytic leukemia" - Advanced course in flow cytometry: applications in Oncology and Immunology. May 22-23, 2012. Verona, Italy

Invited speaker: "Analisi in singola cellula dei profili di signaling del recettore delle cellule B nella leucemia linfoblastica acuta" - Discutiamone Insieme SIES: Le Sindromi linfoproliferative croniche. November 24, 2011. Firenze, Italy

Invited speaker: "Phospho-flow nelle leucemie acute linfoblastiche" - Primo Congresso di Oncoematologia Molecolare. March 26-28, 2010. Torino, Italy

Invited speaker: "Single-cell profiles of B-cell receptor phospho-protein networks associated with prognosis and progression in chronic lymphocytic leukemia". December 22, 2009. Nodality Inc., South San Francisco, CA, USA

Scientific societies

Italian Association of Biology and Genetics (AIBG), since 2018
Italian Society for Cytometric Cell Analysis (ISCCA), since 2016
European Society for Clinical Cell Analysis (ESCCA), since 2014
Italian Society of Experimental Hematology (SIES), since 2007
Italian Society of Immunology (SIICA), since 1994

Publications

Author of 66 articles cited in PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/?term=scupoli>)
Total IF (JCR 2016): 383
Average IF: 5.8
Total citations (Scopus): 1736
Hirsch (H) index (Scopus): 24

List of publications

1. Dalla Pozza E, Dando I, Pacchiana R, Liboi E, **Scupoli MT**, Donadelli M, Palmieri M. Regulation of succinate dehydrogenase and role of succinate in cancer. *Semin Cell Dev Biol*. 2019 May 1
2. Butera G, Mullappilly N, Masetto F, Palmieri M, **Scupoli MT**, Pacchiana R, Donadelli M. Regulation of Autophagy by Nuclear GAPDH and Its Aggregates in Cancer and Neurodegenerative Disorders. *Int J Mol Sci*. 2019 Apr 26;20(9).
3. Conti G, Bertossi D, Dai Prè E, Cavallini C, **Scupoli MT**, Ricciardi G, Parnigotto P, Saban Y, Sbarbati A, Nocini P. Regenerative potential of the Bichat fat pad determined by the quantification of multilineage differentiating stress enduring cells. *Eur J Histochem*. 2018 Oct 23;62(4).
4. Cordani M, Butera G, Dando I, Torrens-Mas M, Butturini E, Pacchiana R, Oppici E, Cavallini C, Gasperini S, Tamassia N, Nadal-Serrano M, Coan M, Rossi D, Gaidano G, Caraglia M, Mariotto S, Spizzo R, Roca P, Oliver J, **Scupoli MT**, Donadelli M. Mutant p53 blocks SESN1/AMPK/PGC-1 α /UCP2 axis increasing mitochondrial O₂⁻ production in cancer cells. *Br J Cancer*. 2018 Oct;119(8):994-1008.
5. Malpeli G, Barbi S, Tosadori G, Greco C, Zupo S, Pedron S, Brunelli M, Bertolaso A, **Scupoli MT**, Krampera M, Kamga PT, Croce CM, Calin GA, Scarpa A, Zamò A. MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. *Oncotarget*. 2018 Jul 3;9(51):29753-29771.
6. Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, Rosanò L, Bonalumi A, Gottardi M, Zanatta L, Giacomazzi A, **Scupoli MT**, Tinelli M, Salvadori U, Mosna F, Zamò A, Cassatella MA, Vinante F, Tecchio C. In reply to Schäfer et al: new evidence on the role of endothelin-1 axis as a potential therapeutic target in multiple myeloma. *Br J Haematol*. 2018 May 4.
7. Malpeli G, Barbi S, Greco C, Zupo S, Bertolaso A, **Scupoli MT**, Krampera M, Kamga PT, Croce CM, Scarpa A, Zamò A. MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. *Oncotarget*. 2018 Apr 13;9(28):19961-19979.
8. Ricci V, Zonari D, Cannito S, Marengo A, **Scupoli MT**, Malatesta M, Carton F, Boschi F, Berlier G, Arpicco S. Hyaluronated mesoporous silica nanoparticles for active targeting: influence of conjugation method and hyaluronic acid molecular weight on the nanovector properties. *J Colloid Interface Sci*. 2018;516:484-497.
9. Cavallini C, Chignola R, Dando I, Perbellini O, Mimiola E, Lovato O, Laudanna C, Pizzolo G, Donadelli M, **Scupoli MT**. Low *catalase* expression confers redox hypersensitivity and identifies an indolent clinical behavior in CLL. *Blood*. 2018;131(17):1942-1954.
10. Parolini F, Biswas P, Serena M, Sironi F, Muraro V, Guizzardi E, Cazzoletti L, **Scupoli MT**, Gibellini D, Ugolotti E, Biassoni R, Beretta A, Malnati M, Romanelli MG, Zipeto D. Stability and Expression Levels of HLA-C on the Cell Membrane Modulate HIV-1 Infectivity. *J Virol*. 2017;92(1). pii: e01711-17.
11. Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, Rosanò L, Bonalumi A, Gottardi M, Zanatta L, Giacomazzi A, **Scupoli MT**, Tinelli M, Salvadori U, Mosna F, Zamò A, Cassatella MA, Vinante F, Tecchio C. Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. *Br J Haematol*. 2017;178(5):781-793.
12. Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampera M, **Scupoli MT**, Nishimura M, Iezzi M, Sartoris S, Bronte V, Ugel S. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. *Oncotarget*. 2017;8(50):86987-87001.
13. Cavallini C, Visco C, Putta S, Rossi D, Mimiola E, Purvis N, Lovato O, Perbellini O, Falisi E, Facco M, Trentin L, Romanelli MG, Semenzato G, Ambrosetti A, Gaidano G, Pizzolo G, Cesano A, **Scupoli MT**. Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of *SF3B1* gene refines prognosis in treatment-naïve chronic lymphocytic leukemia. *Haematologica*. 2017;102(4):e144-e147.
14. Perduca M, Dalle Carbonare L, Bovi M, Innamorati G, Cheri S, Cavallini C, **Scupoli MT**, Mori A, Valenti MT. Runx2 downregulation, migration and proliferation inhibition in melanoma cells treated with BEL β -trefoil. *Oncol Rep*. 2017 Apr;37(4):2209-2214.
15. Marini O, Costa S, Bevilacqua D, Calzetti F, Tamassia N, Spina C, De Sabata D, Tinazzi E, Lunardi C, **Scupoli MT**, Cavallini C, Zoratti E, Tinazzi I, Marchetta A, Vassanelli A, Cantini M, Gandini G, Ruzzenente A, Guglielmi A, Missale F, Vermi W, Tecchio C, Cassatella MA, Scapini P. Mature CD10⁺ and immature CD10⁻ neutrophils present in G-CSF-treated donors display opposite effects on T cells. *Blood*. 2017;129(10):1343-1356.

16. Perucca S, Di Palma A, Piccaluga PP, Gemelli C, Zoratti E, Bassi G, Giacomuzzi E, Lojacono A, Borsani G, Tagliafico E, **Scupoli MT**, Bernardi S, Zanaglio C, Cattina F, Cancelli V, Malagola M, Krampera M, Marini M, Almici C, Ferrari S, Russo D. Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells). *PlosOne*. 2017;12(2):e0172430.
17. Malpeli G, Barbi S, Zupo S, Tosadori G, Scardoni G, Bertolaso A, Sartoris S, Ugel S, Vicentini C, Fassan M, Adamo A, Krampera M, **Scupoli MT**, Croce CM, Scarpa A. Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53. *Oncotarget*. 2017;8(7):11809-11826.
18. Serena M, Parolini F, Biswas P, Sironi F, Blanco Miranda A, Zoratti E, **Scupoli MT**, Ziglio S, Valenzuela-Fernandez A, Gibellini D, Romanelli MG, Siccardi A, Malnati M, Beretta A, Zipeto D. HIV-1 Env associates with HLA-C free-chains at the cell membrane modulating viral infectivity. *Sci Rep*. 2017;7:40037.
19. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Marini O, Spina C, Mimiola E, Cassaro A, Malerba G, Todeschini G, Perbellini O, **Scupoli M**, Carli G, Facchinelli D, Cassatella M, Scapini P, Tecchio C. *Oncotarget*. 2016;7(19):27676-88.
20. Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, **Scupoli MT**, Sartoris S, Iezzi M, Nishimura MI, Bronte V, Ugel S. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. *Cancer Res*. 2016;76(9):2540-51.
21. Cavallini C, Lovato O, Bertolaso A, Zoratti E, Malpeli G, Mimiola E, Tinelli M, Aprili F, Tecchio C, Perbellini O, Scarpa A, Zamò A, Cassatella MA, Pizzolo G, **Scupoli MT**. Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia. *Oncotarget*. 2015;6(31):32061-74.
22. Visco C, Falisi E, Young KH, Pascarella M, Perbellini O, Carli G, Novella E, Rossi D, Giaretta I, Cavallini C, **Scupoli MT**, De Rossi A, D'Amore ES, Rassu M, Gaidano G, Pizzolo G, Ambrosetti A, Rodeghiero F. Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival. *Oncotarget*. 2015;6(21):18653-63.
23. Perbellini O, Cioffi F, Malpeli G, Zanolin E, Lovato O, Scarpa A, Pizzolo G, **Scupoli MT**. Up-regulation of CXCL8/interleukin-8 production in response to CXCL12 in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2014;19:1-4.
24. Granata S, Masola V, Zoratti E, **Scupoli MT**, Baruzzi A, Messa M, Sallustio F, Gesualdo L, Lupo A, Zaza G. NLRP3 inflammasome activation in dialyzed chronic kidney disease patients. *PLoS One*. 2015;10(3):e0122272.
25. Dalla Pozza E, Dando I, Biondani G, Brandi J, Costanzo C, Zoratti E, Fassan M, Boschi F, Melisi D, Cecconi D, **Scupoli MT**, Scarpa A, Palmieri M. Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi-directionally convert into cancer stem cells. *Int J Oncol*. 2015;46(3):1099-108.
26. Perbellini O, Falisi E, Giaretta I, Boscaro E, Novella E, Facco M, Fortuna S, Finotto S, Amati E, Maniscalco F, Montaldi A, Alghisi A, Aprili F, Bonaldi L, Paolini R, **Scupoli MT**, Trentin L, Ambrosetti A, Semenzato G, Pizzolo G, Rodeghiero F, Visco C. Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. *Haematologica*. 2014;99(5):881-7.
27. Valenti MT, Zanatta M, Donatelli L, Viviano G, Cavallini C, **Scupoli MT**, Dalle Carbonare L. Ascorbic acid induces either differentiation or apoptosis in MG-63 osteosarcoma lineage. *Anticancer Res*. 2014;34(4):1617-27.
28. Dalla Pozza E, Lerda C, Costanzo C, Donadelli M, Dando I, Zoratti E, **Scupoli MT**, Beghelli S, Scarpa A, Fattal E, Arpicco S, Palmieri M. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. *Biochim Biophys Acta*. 2013;1828(5):1396-404.
29. Visco C, Moretta F, Falisi E, Facco M, Maura F, Novella E, Nichele I, Finotto S, Giaretta I, Ave E, Perbellini O, Guercini N, **Scupoli MT**, Trentin L, Trimarco V, Neri A, Semenzato G, Rodeghiero F, Pizzolo G, Ambrosetti A. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. *Am J Hematol*. 2013;88(4):277-82.
30. Cavallini C, Lovato O, Bertolaso A, Pacelli L, Zoratti E, Zanolin E, Krampera M, Zamò A, Tecchio C, Cassatella MA, Pizzolo G, **Scupoli MT**. The TNF-family cytokine TL1A inhibits proliferation of human activated B cells. *PlosOne*. 2013;8:e60136.

31. Cesano A, Perbellini O, Evensen E, Chu CC, Cioffi F, Ptacek J, Damle RN, Chignola R, Cordeiro J, Yan XJ, Hawtin RE, Nichele I, Ware JR, Cavallini C, Lovato O, Zanotti R, Rai KR, Chiorazzi N, Pizzolo G, **Scupoli MT**. Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies. *Haematologica*. 2013;98(4):626-34.
32. **Scupoli MT**, Pizzolo G. Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. *Expert Rev Hematol*. 2012; 5:341-8. Review.
33. Dehecchi MC, Nicolis E, Mazzi P, Cioffi F, Bezzeri V, Lampronti I, Huang S, Wiszniewski L, Gambari R, **Scupoli MT**, Berton G, Cabrini G. Modulators of sphingolipid metabolism reduce lung inflammation. *Am J Respir Cell Mol Biol*. 2011;45(4):825-33.
34. Nwabo Kamdje AH, Mosna F, Bifari F, Lisi V, Bassi G, Malpeli G, Ricciardi M, Perbellini O, **Scupoli MT**, Pizzolo G, Krampera M. Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. *Blood*. 2011;14;118(2):380-9.
35. Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla Pozza E, **Scupoli MT**, Scarpa A, Zappavigna S, Marra M, Abbruzzese A, Bifulco M, Caraglia, M Palmieri M. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. *Cell Death and Disease*. 2011; 2, e152.
36. Dalla Pellegrina C, Perbellini O, **Scupoli MT**, Tomelleri C, Zanetti C, Zoccatelli G, Fusi M, Peruffo A, Rizzi C, Chignola R. Effects of wheat germ agglutinin on human gastrointestinal epithelium: insights from an experimental model of immune/epithelial cell interaction. *Toxicol Appl Pharmacol*. 2009;237(2):146-53.
37. Cecconi D, Donadelli M, Dalla Pozza E, Rinalducci S, Zolla L, **Scupoli MT**, Righetti PG, Scarpa A, Palmieri M. Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. *Proteomics*. 2009 Apr;9(7):1952-66.
38. Donadelli M, Dalla Pozza E, **Scupoli MT**, Costanzo C, Scarpa A, Palmieri M. Intracellular zinc increase inhibits p53(-/-) pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis. *Biochim Biophys Acta*. 2009;1793(2):273-80.
39. Perbellini O, **Scupoli MT**. Adult T-cell acute lymphoblastic leukemia: prognostic impact of myeloid-associated antigens. *Expert Rev Hematol*. 2009;2(1):27-9.
40. Colombatti M, Grasso S, Porzia A, Fracasso G, **Scupoli MT**, Cingarlini S, Poffe O, Naim HY, Heine M, Tridente G, Mainiero F, Ramarli D. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. *PLoS One*. 2009;4(2):e4608.
41. Donadelli M, Dalla Pozza E, Costanzo C, **Scupoli MT**, Scarpa A, Palmieri M. Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes. *J Cell Biochem*. 2008;104(1):202-12.
42. **Scupoli MT**, Donadelli M, Cioffi F, Rossi M, Perbellini O, Malpeli G, Corbioli S, Vinante F, Krampera M, Palmieri M, Scarpa A, Ariola C, Foà R, and Pizzolo G. Bone marrow stromal cells up-regulate interleukin 8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF- κ B and JNK/AP-1 pathways. *Haematologica*. 2008; 93:524-532.
43. Tomelleri C, Milotti E, Dalla Pellegrina C, Perbellini O, Del Fabbro A, **Scupoli MT**, Chignola R.A quantitative study of growth variability of tumour cell clones in vitro. *Cell Prolif*. 2008;41(1):177-91.
44. Donadelli M, Costanzo C, Beghelli S, **Scupoli MT**, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A, Palmieri M. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. *Biochim Biophys Acta*. 2007; 1773:1095-106.
45. Cecconi D, Donadelli M, Rinalducci S, Zolla L, **Scupoli MT**, Scarpa A, Palmieri M, Righetti PG. Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. *Proteomics*. 2007;7(10):1644-53.
46. **Scupoli MT**, Perbellini O, Krampera M, Vinante F, Cioffi F, Pizzolo G. Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. *Haematologica*. 2007; 92:264-266.
47. Donadelli M, Dalla Pozza E, Costanzo C, **Scupoli MT**, Piacentini P, Scarpa A, Palmieri M. Increased stability of P21(WAF1/CIP1) mRNA is required for ROS/ERK-dependent pancreatic adenocarcinoma cell growth inhibition by pyrrolidine dithiocarbamate. *Biochim Biophys Acta*. 2006;1763(9):917-26.
48. Krampera M, Perbellini O, Vincenzi C, Zampieri F, Pasini A, **Scupoli MT**, Guarini A, De Propriis MS, Coustan-Smith E, Campana D, Foà R, Pizzolo G. Methodological approach to minimal residual disease

- detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. *Haematologica*. 2006;91(8):1109-12.
49. Krampera M, Pasini A, Rigo A, **Scupoli MT**, Tecchio C, Malpeli G, Scarpa A, Dazzi F, Pizzolo G, Vinante F. HB-EGF/HER -1 signalling in bone marrow mesenchymal stem cells: inducing cell expansion and preventing reversibly multi-lineage differentiation. *Blood*. 2005; 106: 59-66.
 50. **Scupoli MT**, Vinante F, Krampera M, Vincenzi C, Nadali G, Zampieri F, Ritter MA, Eren E, Santini F, Pizzolo G. Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. *Haematologica*. 2003;88:1229-1237.
 51. Donadelli M, Costanzo C, Faggioli L, **Scupoli MT**, Moore PS, Bassi C, Scarpa A, Palmieri M. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. *Mol Carcinog*. 2003;38(2):59-69.
 52. Vinante F, Rigo A, **Scupoli MT**, Pizzolo G. CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540. *Blood*. 2002;99:52-60.
 53. Krampera M, Fattovich G, **Scupoli MT**, Pizzolo G. Early decrease of interferon-gamma+ and interleukin-2+ T cells during combination treatment with interferon-alpha and ribavirin in patients with chronic hepatitis C. *Am J Gastroenterol*. 2000;95(12):3670-3.
 54. Fiorini E, Marchisio PC, **Scupoli MT**, Poffe O, Tagliabue E, Brentegani M, Colombatti M, Santini F, Tridente G, Ramarli D. Adhesion of immature and mature T cells induces in human thymic epithelial cells (TEC) activation of IL-6 gene transcription factors (NF-kappaB and NF-IL6) and IL-6 gene expression: role of alpha3beta1 and alpha6beta4 integrins. *Dev Immunol*. 2000;7:195-208.
 55. **Scupoli MT**, Fiorini E, Marchisio PC, Poffe O, Tagliabue E, Cecchini G, Brentegani M, Tridente G, Ramarli D. Lymphoid adhesion promotes human thymic epithelial cell survival via NF-kappaB activation. *J Cell Sci*. 2000;113:169-177.
 56. Ramarli D, **Scupoli MT**, Fiorini E, Poffe O, Brentegani M, Villa A, Cecchini G, Tridente G, Marchisio PC. Thymocyte contact or monoclonal antibody-mediated clustering of alpha3beta1 or alpha6beta4 integrins activate interleukin-6 (IL-6) transcription factors (NF-kappaB and NF-IL6) and IL-6 production in human thymic epithelial cells. *Blood*. 1998;92:3745-3755.
 57. Achille A, **Scupoli MT**, Magalini AR, Zamboni G, Romanelli MG, Orlandini S, Biasi MO, Lemoine NR, Accolla RS, Scarpa A. APC gene mutations and allelic losses in sporadic ampullary tumours: evidence of genetic difference from tumours associated with familial adenomatous polyposis. *Int J Cancer*. 1996;68(3):305-12.
 58. Paganin C, Gerosa F, Peritt D, Paiola F, **Scupoli MT**, Aste-Amezaga M, Frank I, Trinchieri G. Effect of interleukin-12 on the cytokine profile of human CD4 and CD8 T-cell clones. *Ann N Y Acad Sci*. 1996;795:382-3.
 59. Ramarli D, Reina S, Merola M, **Scupoli MT**, Poffe O, Brentegani M, Fiorini E, Vella A, Varnier O, Tridente G. HTLV-IIIb infection of human thymic epithelial cells: viral expression correlates with the induction of NF-kappaB binding activity in cells activated by cell adhesion. *AIDS Res Hum Retrov*. 1996;12:1217-1225.
 60. **Scupoli MT**, Sartoris S, Tosi G, Ennas MG, Nicolis M, Cestari T, Zamboni G, Martignoni G, Lemoine NR, Scarpa A, Accolla RS. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. *Tissue Antigens*. 1996;48:301-311.
 61. Gerosa F, Paganin C, Peritt D, Paiola F, **Scupoli MT**, Aste-Amezaga M, Frank I, Trinchieri G. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. *J Exp Med*. 1996;183:2559-2569.
 62. **Scupoli MT**, Cestari T, Nicolis M, Cambiaggi C, Rocchi M, Accolla RS. Interspecies somatic T cell hybrids as biological tools for studying gene expression during T cell development. *Int J Clin Lab Res*. 1994;24:203-207.
 63. **Scupoli MT**, Sartoris S, Nicolis N, Cestari T, Cambiaggi C, Tridente G, Accolla RS. Evidence for a trans-acting activator function regulating the expression of the human CD5 antigen. *Immunogenetics*. 1991;40:217-221.
 64. Cambiaggi C, **Scupoli MT**, Cestari T, Gerosa F, Carra G, Tridente G, Accolla RS. Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12. *Immunogenetics*. 1992;36(2):117-20.
 65. Accolla RS, **Scupoli MT**, Cambiaggi C, Tosi G, Sartoris S. Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression. *Int J Cancer Suppl*. 1991;6:20-5. Review.

66. Sartoris S, **Scupoli MT**, Scarpellino L, Paiola F, Jotterand-Bellomo M, Tridente G, Accolla RS. Inducible and constitutive MHC class II gene expression. J Immunol. 1990;145:1960-1967.

Patents

Patent #TO2011A000233: METHODS FOR DIAGNOSIS, PROGNOSIS, AND TREATMENT OF HEMATOPOIETIC DISORDERS, deposited on March 11, 2011. University of Verona and Nodality Inc. (USA). Inventors: Maria Teresa SCUPOLI, Erik EVENSEN



May 16, 2019